Sign In
Buy HZNP
$116.30
+0 (+0%)
At Close: Jan 04, 2024
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
09:33pm, Wednesday, 02'nd Nov 2022
The company released encouraging year-end guidance.
Horizon Therapeutics Public Limited Company (HZNP) Q3 2022 Earnings Call Transcript
12:27pm, Wednesday, 02'nd Nov 2022
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP ) Q3 2022 Results Conference Call November 2, 2022 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relatio
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
10:32am, Friday, 30'th Sep 2022
Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal
05:18pm, Tuesday, 13'th Sep 2022
Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Why Horizon Therapeutics Is One Of The Best Investments In Biotech Today
01:25pm, Wednesday, 31'st Aug 2022
Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at
Why Viridian's CEO Isn't Sweating His Company's Second-Place Position
08:00am, Wednesday, 31'st Aug 2022
Viridian Therapeutics hopes to follow Horizon Therapeutics with a best thyroid eye disease drug, and the IPO stock is on a run. The post Why Viridian's CEO Isn't Sweating His Company's Second-Place Po
Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe
03:02pm, Tuesday, 23'rd Aug 2022
Horizon's (HZNP) portfolio of marketed drugs, including Tepezza and Krystexxa, aid growth. The company is also working on the label expansion of its drugs.
Horizon Therapeutics: This Core Biotech Company Is On Sale
05:00am, Friday, 19'th Aug 2022
Shares have lost 40% of their value year to date. Tepezza sales should reaccelerate into the back half of 2022 and 2023 as the drug makes inroads into chronic TED market.
New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets
11:32am, Monday, 15'th Aug 2022
Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged. The post New Contender Viridian Takes Aim At Horizon's Eye Drug,
Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
12:47pm, Wednesday, 03'rd Aug 2022
Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022.
Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2022 Results - Earnings Call Transcript
10:43am, Wednesday, 03'rd Aug 2022
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP ) Q2 2022 Results Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Lag Estimates
09:47am, Wednesday, 03'rd Aug 2022
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -20.74% and 6.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Horizon Therapeutics (HZNP) Might Surprise This Earnings Season
10:35am, Tuesday, 02'nd Aug 2022
Horizon Therapeutics (HZNP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth
08:18am, Sunday, 31'st Jul 2022
Horizon Therapeutics roared past the $100 per share mark in mid-2021 as I predicted it would do in a 2020 note for SA. The company's share price has dipped in 2022, however, and with Q2 '22 earnings d
